Veru (VERU) Projected to Post Quarterly Earnings on Thursday

Veru (NASDAQ:VERU) will likely be announcing its Q1 2026 results before the market opens on Thursday, February 12th. Analysts expect the company to announce earnings of ($0.33) per share for the quarter. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 8:00 AM ET.

Veru (NASDAQ:VERU) last issued its quarterly earnings results on Wednesday, December 17th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.18. During the same quarter in the previous year, the company posted ($0.28) earnings per share. On average, analysts expect Veru to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Veru Trading Down 1.2%

Shares of NASDAQ:VERU opened at $2.53 on Thursday. Veru has a 52 week low of $2.10 and a 52 week high of $7.40. The company’s 50 day moving average is $2.44 and its two-hundred day moving average is $3.22. The company has a market cap of $40.61 million, a PE ratio of -1.15 and a beta of -1.42.

Institutional Trading of Veru

A number of large investors have recently made changes to their positions in VERU. Northwestern Mutual Wealth Management Co. purchased a new position in Veru during the 3rd quarter worth approximately $38,000. Jacobs Levy Equity Management Inc. purchased a new position in shares of Veru during the third quarter worth approximately $110,000. XTX Topco Ltd purchased a new position in shares of Veru during the second quarter worth approximately $49,000. Bank of America Corp DE increased its holdings in shares of Veru by 5.5% in the 2nd quarter. Bank of America Corp DE now owns 185,669 shares of the company’s stock valued at $108,000 after acquiring an additional 9,637 shares during the period. Finally, Raymond James Financial Inc. raised its position in Veru by 48.3% in the 2nd quarter. Raymond James Financial Inc. now owns 206,405 shares of the company’s stock valued at $120,000 after purchasing an additional 67,178 shares during the last quarter. 47.16% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have weighed in on VERU shares. Oppenheimer restated an “outperform” rating on shares of Veru in a research note on Thursday, December 18th. Wall Street Zen lowered Veru from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Weiss Ratings restated a “sell (e+)” rating on shares of Veru in a research note on Wednesday, January 21st. Finally, Canaccord Genuity Group began coverage on shares of Veru in a research note on Thursday, December 18th. They issued a “buy” rating and a $25.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Veru Company Profile

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.